New obesity drug tested in healthy men – early safety results expected
NCT ID NCT06542536
First seen Nov 18, 2025 · Last updated May 22, 2026 · Updated 23 times
Summary
This early-stage study tested a single oral dose of the experimental drug monlunabant in 73 healthy men of normal weight, half Japanese and half Caucasian. The main goal was to check safety and how the drug moves through the body. Participants were randomly assigned to receive monlunabant, placebo, or both, and were followed for about 49 days.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Altasciences Clinical LA, Inc.
Cypress, California, 90630, United States
Conditions
Explore the condition pages connected to this study.